Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aidan Fry

With over 20 years of experience of reporting on the global pharmaceutical industry, Aidan focuses in his role as editor of Generics bulletin particularly on commercial, regulatory and legal issues affecting the generic, biosimilar, value-added and OTC medicines industries. This includes in-depth analyses of corporate strategy, legislative changes, legal precedents and product perspectives. He regularly interviews leading industry executives and moderates prestigious events. Aidan also oversees the Global Generics & Biosimilars Awards. Aidan speaks fluent German and has a particular affection for maps.
Set Alert for Articles By Aidan Fry

Latest From Aidan Fry

Egypt’s Rameda Prices Public Offering

Through an initial public offering, Egyptian branded generics supplier Rameda intends to raise funds to buy both products and companies in the Middle East and North Africa.

Business Strategies Middle East and Africa

Ophthalmics Are Next Frontier For Teligent

US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.


Ophthalmic Business Strategies

IPA Honors DG Shah With Public-Policy Award

In honor of its former secretary-general DG Shah, the Indian Pharmaceutical Alliance has created a public policy award at the Indian Institute of Management in Ahmedabad.

India Policy

Advanz Sees Mumbai Center As Strategic Strength

Using its Indian back-office function to realize synergies from acquired sales and marketing assets in western Europe forms a key part of Advanz Pharma’s growth strategy.

Business Strategies M & A

Emcure Aims To Split Itself In Half

By the middle of next year, Emcure intends to have demerged its operations in highly developed markets from its activities in India and other emerging markets. The Indian group is seeking private-equity support to grow inorganically in North America and Europe.

Business Strategies United States

Hikma Sets Injectables Sights On France, Spain and Canada

With added steriles capacity coming online, Hikma is looking soon to expand its Injectables business unit into France and Spain. The company is also considering options for marketing injectable drugs in Canada.

See All